Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Radiation for Head and Neck Mucosal Melanoma
NCT03758729Phase 2Withdrawn
- Sponsor
- Samsung Medical Center
- Start
- May 2020
- Primary completion
- May 2020
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of nivolumab in mucosal melanoma (MM), sponsored by Samsung Medical Center. Planned start May 2020; status: withdrawn.
02
Drugs
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT03758729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03758729.